Ardelyx (FRA:41X) Additional Paid-In Capital : €991.7 Mil(As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Additional Paid-In Capital?

Ardelyx's quarterly additional paid-in capital increased from Sep. 2024 (€944.3 Mil) to Dec. 2024 (€1,010.9 Mil) but then stayed the same from Dec. 2024 (€1,010.9 Mil) to Mar. 2025 (€991.7 Mil).

Ardelyx's annual additional paid-in capital increased from Dec. 2022 (€829.3 Mil) to Dec. 2023 (€928.7 Mil) and increased from Dec. 2023 (€928.7 Mil) to Dec. 2024 (€1,010.9 Mil).

Ardelyx Additional Paid-In Capital Historical Data

The historical data trend for Ardelyx's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Additional Paid-In Capital Chart

Ardelyx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

559.68

704.05

829.30

928.71

1,010.91

Ardelyx Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															941.72	962.67	944.31	1,010.91	991.71

Ardelyx Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Ardelyx Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ardelyx's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ARDX:USA 41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Headlines

No Headlines